Blogging platform Jianshu – aka “China’s Medium” – receives USD 6 M for Series B round
Founder: Lin Li
Founded in: 2013
Financing status: RMB 42 million (USD 6 million) Series B financing in 2017
Jianshu, a popular blogging platform also known as China’s Medium, enables users to express themselves by sharing their original written content on the platform’s simple layout. Users can also share content on specific topics in Jianshu’s community. Founded in 2013 in Shanghai, Jianshu has attracted more than 1 million writers who have contributed to more than 10 million stories so far. About 40,000 new stories are being published daily.
This Series B financing round was led by Legend Capital and Susquehanna International Group, and the funds will be used to expand marketing plans, and increase its investment on technology to seek a new business model.
CanSinoBio’s vaccine R&D goals receive USD 65 M for Series C round
Founder: Yu Xuefeng
Founded in: 2009
Financing status: RMB 450 million (USD 65 million) Series C financing in 2017
CanSinoBio is a biotechnology company dedicated to the research and development, manufacturing and commercialization of high value and high quality vaccine products. CanSinoBio is a Tianjin company founded in 2009, and has invested in the research and development of more than 10 vaccines for disease prevention. These diseases include pneumonia, tuberculosis, Ebola virus disease, meningitis, diphtheria, and so on. Four of its vaccines have entered clinical research in North America, Africa and China, with three vaccines waiting for clinical approval to enter the market.
CanSinoBio’s vaccines will be mainly sold in China and other emerging countries at an affordable cost. It also aims to capture these markets with its cutting edge scientific resources and technology.
This Series C funding round was led by SDIC Fund Management, and the company will use this fund to accelerate the development of vaccine products and speed up its product supply capabilities.
(Top photo from 58pic.com)